Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Achrochordon Clear all
Terminated No phase listed Observational

A-SPIRE Heart Failure: Utilizing Health Tags to Identify Patients at Risk for Hospital Readmissions

NCT04550052
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 3, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms

NCT00590759
View directory record Official record
Conditions
Aortic Aneurysm, Thoracic
Interventions
GORE TAG® Thoracic Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Sep 3, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic

NCT00874250
View directory record Official record
Conditions
Aneurysm
Interventions
GORE CTAG Device
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
21 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 3, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease

NCT00757003
View directory record Official record
Conditions
Aneurysm, Dissecting, Aortic Aneurysm, Thoracic
Interventions
Endovascular Stent-graft repair of descending thoracic aorta
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 3, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery

NCT03202472
View directory record Official record
Conditions
Breast Neoplasm, Lesion
Interventions
Implanted Medical Device, Mammography, Questionnaire Administration, Radiofrequency (RFID) -Guided Localization, Ultrasonography
Device · Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 3, 2026, 1:09 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Using a Novel Skin Tag Removal Device

NCT06463613
View directory record Official record
Conditions
Achrochordon
Interventions
STR Skin Tag Removal device with diary and follow-up
Device
Lead sponsor
UK Innovations GP LTD
Industry
Eligibility
22 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 3, 2026, 1:09 AM EDT
Terminated Phase 1 Interventional

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

NCT05716009
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 3, 2026, 1:09 AM EDT
Completed No phase listed Observational

Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)

NCT02224677
View directory record Official record
Conditions
Craniofacial Microsomia, Hemifacial Microsomia, Oculo-Auriculo-Vertebral-Syndrome, Goldenhar Syndrome, Microtia
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
12 Months to 24 Months
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 3, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms

NCT02021812
View directory record Official record
Conditions
Aortic Aneurysm, Thoracic
Interventions
GORE® TAG® Thoracic Branch Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
6
States / cities
Stanford, California • Ann Arbor, Michigan • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Sep 3, 2026, 1:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Evaluate the Efficacy of Removing Skin Tags With Digiclamp

NCT03259295
View directory record Official record
Conditions
Achrochordon
Interventions
Digiclamp (Skin tag removal initial plus follow-up)
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ocala, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 3, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

Early Feasibility of the Branched TAG® Device in the Treatment of Aortic Arch Aneurysms

NCT02264977
View directory record Official record
Conditions
Aneurysm of Aortic Arch
Interventions
GORE® TAG® Thoracic Branch Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
Stanford, California • Ann Arbor, Michigan • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 3, 2026, 1:09 AM EDT
Recruiting Not applicable Interventional

GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study

NCT07166133
View directory record Official record
Conditions
Aortic Arch Dissection, Aortic Arch Aneurysm
Interventions
GORE® TAG® Thoracic Branch Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Hartford, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 3, 2026, 1:09 AM EDT
Active, not recruiting Not applicable Interventional Results available

Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 0/1

NCT02777528
View directory record Official record
Conditions
Aortic Aneurysm, Thoracic, Aorta, Lesion
Interventions
GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure
Device · Procedure
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
34
States / cities
Los Angeles, California • Stanford, California • Hartford, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 3, 2026, 1:09 AM EDT
Recruiting No phase listed Observational

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

NCT06658730
View directory record Official record
Conditions
Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta, Aneurysm Thoracic, Aneurysm Dissecting, Transection Aorta, Intramural Hematoma
Interventions
Endovascular
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2038
U.S. locations
24
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 1:09 AM EDT
Terminated Phase 1 Interventional

Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer

NCT00684294
View directory record Official record
Conditions
Carcinoma, Advanced Metastatic
Interventions
TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine
Biological
Lead sponsor
Mary Crowley Medical Research Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 3, 2026, 1:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spire Medical Health Tag Actigraphy and Sleep Validation in Adults

NCT04102709
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Health Tag
Device
Lead sponsor
Spire, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 3, 2026, 1:09 AM EDT
Completed Early Phase 1 Interventional

SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer

NCT03411070
View directory record Official record
Conditions
Positive Axillary Lymph Node, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Implanted Medical Device, Therapeutic Conventional Surgery
Device · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 3, 2026, 1:09 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

NCT06414681
View directory record Official record
Conditions
Myelofibrosis，MF
Interventions
Tagraxofusp, Pacritinib
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 3, 2026, 1:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Spire Medical Health Tag Respiratory Rate Validation in Adults

NCT04104737
View directory record Official record
Conditions
Respiratory Rate
Interventions
Spire Medical Health Tag
Device
Lead sponsor
Spire, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
San Francisco, California • Louisville, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 3, 2026, 1:09 AM EDT
Active, not recruiting Not applicable Interventional Results available

Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2

NCT02777593
View directory record Official record
Conditions
Aortic Aneurysm, Thoracic, Aorta; Lesion
Interventions
GORE® TAG® Thoracic Branch Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
35
States / cities
Los Angeles, California • Stanford, California • Hartford, Connecticut + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 3, 2026, 1:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhanced Internet Behavior Therapy for Treating Obesity

NCT00212238
View directory record Official record
Conditions
Obesity
Interventions
internet behavioral weight loss program
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Sep 3, 2026, 1:09 AM EDT
Recruiting Phase 2 Interventional

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

NCT07497399
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
NLY01, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 3, 2026, 1:09 AM EDT
Completed Not applicable Interventional

HCV Tappt Adherence Study

NCT06263829
View directory record Official record
Conditions
Hepatitis C
Interventions
Use of Tappt App
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 1:09 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

NCT02661022
View directory record Official record
Conditions
Multiple Myeloma
Interventions
SL-401 7 µg/kg/day, SL-401 9 µg/kg/day
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 3, 2026, 1:09 AM EDT